Suchergebnisse - "Nguyen, Bach"

PubPharm (10)

1

Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response : a sub-study of the NEAT001/ANRS143 randomized trial

enthalten in: The Journal of antimicrobial chemotherapy | 2020

von Dickinson, L. | Gurjar, R. | Stöhr, W. | +113

2

Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection : a randomised, double-blind, parallel-group, phase 3, non-inferiority trial

enthalten in: The lancet. HIV | 2017

von Cahn, P. | Kaplan, R. | Sax, P. | +122

CommentIn: Lancet HIV. 2017 Nov;4(11):e476-e477. - PMID 28918878

3

Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1 : a substudy of the NEAT001/ANRS143 randomised trial

enthalten in: The lancet. HIV | 2015

von Bernardino, J. | Mocroft, A. | Mallon, P. | +115

CommentIn: Lancet HIV. 2015 Nov;2(11):e452-3. - PMID 26520920

4

Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1 : 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial

enthalten in: Lancet (London, England) | 2014

von Raffi, F. | Babiker, A. | Richert, L. | +117

CommentIn: Lancet. 2014 Nov 29;384(9958):1908-10. - PMID 25103175

5

Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients : final 5-year results from STARTMRK

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2013

von Rockstroh, J. | DeJesus, E. | Lennox, J. | +80

6

Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients : week-192 overall and subgroup analyses from STARTMRK

enthalten in: HIV clinical trials | 2012

von DeJesus, E. | Rockstroh, J. | Lennox, J. | +80

ErratumIn: HIV Clin Trials. 2012 Sep-Oct;13(5):preceding 233

7

Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients : 156-week results from STARTMRK

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2011

von Rockstroh, J. | Lennox, J. | Dejesus, E. | +13

8

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection : a multicentre, double-blind randomised controlled trial

enthalten in: Lancet (London, England) | 2009

von Lennox, J. | DeJesus, E. | Lazzarin, A. | +81

ErratumIn: Lancet. 2009 Dec 19-2010 Jan 1;374(9707):2054

9

Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase

enthalten in: AIDS (London, England) | 2007

von Murray, J. | Emery, S. | Kelleher, A. | +6

10

Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection : results of a 48-week controlled study

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2007

von Markowitz, M. | Nguyen, B. | Gotuzzo, E. | +13

1
[1]